Domains of apoE4 required for the biogenesis of apoE-containing HDL

Annals of Medicine

Volumn 43, Issue 4, 2011, Pages 302-311

  Vezeridis, Alexander M ^a   Chroni, Angeliki ^b   Zannis, Vassilis I ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b National Center for Research Demokritos   (Greece)

Author keywords

Apolipoprotein E; HDL biogenesis; HDL gene transfer; LCAT

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN E4; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ARTICLE; BIOGENESIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; ELECTRON MICROSCOPY; ENZYME ACTIVATION; FAST PROTEIN LIQUID CHROMATOGRAPHY; FEMALE; GENE TRANSFER; MALE; MOUSE; NONHUMAN; NULL ALLELE; PRIORITY JOURNAL; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ADENOVIRIDAE; ANIMALS; APOLIPOPROTEIN A-I; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; ATP-BINDING CASSETTE TRANSPORTERS; FEMALE; HUMANS; LIPOPROTEINS; LIPOPROTEINS, HDL; MALE; METABOLIC NETWORKS AND PATHWAYS; MICE; MICE, KNOCKOUT; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; RNA, MESSENGER; TRANSDUCTION, GENETIC;

EID: 79957483037     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2010.549143     Document Type: Article

References (45)

1. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein Edeficientmice created by homologous recombination in ES cells. Cell. 1992;71:343-53.
2. Schaefer EJ, Gregg RE, Ghiselli G, Forte TM, Ordovas JM, Zech LA, et al. Familial apolipoprotein Edeficiency. J Clin Invest. 1986;78:1206-19.
3. Reddick RL, Zhang SH, Maeda N. Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression. Arterioscler Thromb. 1994;14:141-7.
4. Herz J, Willnow TE. Lipoprotein and receptor interactions in vivo. Curr Opin Lipidol. 1995;6:97-103.
5. Kim DH, Iijima H, Goto K, Sakai J, Ishii H, Kim HJ, et al. Human apolipoprotein E receptor 2. A novel lipopro-tein receptor of the low density lipoprotein receptor family predominantly expressed in brain. J Biol Chem. 1996; 271:8373-80.
6. Takahashi S, Kawarabayasi Y, Nakai T, Sakai J, Yamamoto T. Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specifi -city. Proc Natl Acad Sci USA. 1992;89:9252-6.
7. Kypreos KE, Zannis VI. Pathway of biogenesis of apolipo-protein E-containing HDL in vivo with the participation of ABCA1 and LCAT. Biochem J. 2007;403:359-67. (Pubitemid 46596593)
8. Zannis VI, Koukos G, Drosatos K, Vezeridis A, Zanni EE, Kypreos KE, et al. Discrete roles of apoA-I and apoE in the biogenesis of HDL species: lessons learned from gene transfer studies in different mouse models. Ann Med. 2008;40 Suppl 1:14-28. (Pubitemid 351199339)
9. Hughes SD, Verstuyft J, Rubin EM. HDL defi ciency in genetically engineered mice requires elevated LDL to accelerate atherogenesis. Arterioscler Thromb Vasc Biol. 1997;17: 1725-9. (Pubitemid 27423993)
10. Voyiaziakis E, Goldberg IJ, Plump AS, Rubin EM, Breslow JL, Huang LS. ApoA-I defi ciency causes both hypertriglyc-eridemia and increased atherosclerosis in human apoB trans-genic mice. J Lipid Res. 1998;39:313-21. (Pubitemid 28100669)
11. Zannis VI, Just PW, Breslow JL. Human apolipoprotein E isoprotein subclasses are genetically determined. Am J Hum Genet. 1981;33:11-24. (Pubitemid 11188459)
12. Zannis VI, Zanni EE, Makrides SC, Kardassis D, Aleshkov S. Role of apolipoprotein E in Alzheimer's disease. In: Catravas JD, editor. NATO ASI Series, Life Sciences. New York: Plenum Press; 1998. p. 179-209.
13. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921-3. (Pubitemid 23275809)
14. Boyles JK, Pitas RE, Wilson E, Mahley RW, Taylor JM. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J Clin Invest. 1985;76:1501-13. (Pubitemid 16193568)
15. Koldamova R, Staufenbiel M, Lefterov I. Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J Biol Chem. 2005;280: 43224-35. (Pubitemid 43049289)
16. Wahrle SE, Jiang H, Parsadanian M, Hartman RE, Bales KR, Paul SM, et al. Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J Biol Chem. 2005;280:43236-42. (Pubitemid 43049290)
17. Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A, et al. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest. 2008;118:671-82. (Pubitemid 351206556)
18. Chroni A, Liu T, Gorshkova I, Kan HY, Uehara Y, Von Eckardstein A, et al. The central helices of apoA-I can promote ATP-binding cassette transporter A1 (ABCA1)-mediated lipid effl ux. Amino acid residues 220-231 of the wild-type apoA-I are required for lipid effl ux in vitro and high density lipoprotein formation in vivo. J Biol Chem. 2003;278:6719-30. (Pubitemid 36800659)
19. Liu T, Krieger M, Kan HY, Zannis VI. The effects of mutations in helices 4 and 6 of apoA-I on scavenger receptor class B type I (SR-BI)-mediated cholesterol effl ux suggest that formation of a productive complex between reconstituted high density lipoprotein and SR-BI is required for effi cient lipid transport. J Biol Chem. 2002;277:21576-84. (Pubitemid 34952304)
20. Kypreos KE, Van Dijk KW, Van Der Zee A, Havekes LM, Zannis VI. Domains of apolipoprotein E contributing to trig-lyceride and cholesterol homeostasis in vivo. Carboxyl-terminal region 203-299 promotes hepatic very low density lipoprotein-triglyceride secretion. J Biol Chem. 2001;276: 19778-86.
21. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplifi ed system for generating recombinant adenovi-ruses. Proc Natl Acad Sci USA. 1998;95:2509-14. (Pubitemid 28145972)
22. Chroni A, Kan HY, Shkodrani A, Liu T, Zannis VI. Deletions of helices 2 and 3 of human apoA-I are associated with severe dyslipidemia following adenovirus-mediated gene transfer in apoA-I-defi cient mice. Biochemistry. 2005;44: 4108-17. (Pubitemid 40358064)
23. Chroni A, Nieland TJ, Kypreos KE, Krieger M, Zannis VI. SR-BI mediates cholesterol effl ux via its interactions with lipid-bound ApoE. Structural mutations in SR-BI diminish cholesterol effl ux. Biochemistry. 2005;44:13132-43. (Pubitemid 41377293)
24. Chroni A, Duka A, Kan HY, Liu T, Zannis VI. Point mutations in apolipoprotein a-I mimic the phenotype observed in patients with classical lecithin:cholesterol acyltransferase defi ciency. Biochemistry. 2005;44:14353-66. (Pubitemid 41534670)
25. Li X, Kypreos K, Zanni EE, Zannis V. Domains of apoE required for binding to apoE receptor 2 and to phospholip-ids: Implications for the functions of apoE in the brain. Biochemistry. 2003;42:10406-17. (Pubitemid 37071440)
26. Fielding CJ, Fielding PE. Two-dimensional nondenaturing electrophoresis of lipoproteins: applications to high-density lipoprotein speciation. Methods Enzymol. 1996;263:251-9. (Pubitemid 26001892)
27. Chroni A, Kan HY, Kypreos KE, Gorshkova IN, Shkodrani A, Zannis VI. Substitutions of glutamate 110 and 111 in the middle helix 4 of human apolipoprotein A-I (apoA-I) by alanine affect the structure and in vitro functions of apoA-I and induce severe hypertriglyceridemia in apoA-I-defi cient mice. Biochemistry. 2004;43:10442-57. (Pubitemid 39079318)
28. Hill JS, O K, Wang X, Paranjape S, Dimitrijevich D, Lacko AG, et al. Expression and characterization of recombinant human lecithin:cholesterol acyltransferase. J Lipid Res. 1993;34:1245-51. (Pubitemid 23199172)
29. Jin L, Lee YP, Jonas A. Biochemical and biophysical characterization of human recombinant lecithin: cholesterol acyl-transferase. J Lipid Res. 1997;38:1085-93. (Pubitemid 27281804)
30. Amar MJA, Shamburek RD, Foger B, Hoyt RF, Wood DO, Santamarina-Fojo S, et al. Adenovirus-mediated expression of LCAT in non-human primates leads to an antiatherogenic lipoprotein profi le with increased HDL and decreased LDL. Circulation. 1998;98:35.
31. Laccotripe M, Makrides SC, Jonas A, Zannis VI. The carboxyl-terminal hydrophobic residues of apolipoprotein A-I affect its rate of phospholipid binding and its association with high density lipoprotein. J Biol Chem. 1997;272:17511-22. (Pubitemid 27311184)
32. Matz CE, Jonas A. Micellar complexes of human apolipo-protein A-I with phosphatidylcholines and cholesterol prepared from cholate-lipid dispersions. J Biol Chem. 1982;257: 4535-40.
33. Li X, Kan HY, Lavrentiadou S, Krieger M, Zannis V. Reconstituted discoidal apoE-phospholipid particles are ligands for the scavenger receptor BI. The amino-terminal 1-165 domain of apoE suffi ces for receptor binding. J Biol Chem. 2002;277: 21149-57. (Pubitemid 34952250)
34. Zannis VI, Chroni A, Krieger M. Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J Mol Med. 2006;84:276-94.
35. Chroni A, Koukos G, Duka A, Zannis VI. The carboxy-terminal region of apoA-I is required for the ABCA1-dependent formation of alpha-HDL but not prebeta-HDL particles in vivo. Biochemistry. 2007;46:5697-708. (Pubitemid 46764119)
36. Aggerbeck LP, Wetterau JR, Weisgraber KH, Wu CS, Lind-gren FT. Human apolipoprotein E3 in aqueous solution. II. Properties of the amino- and carboxyl-terminal domains. J Biol Chem. 1988;263:6249-58.
37. Wetterau JR, Aggerbeck LP, Rall SC Jr, Weisgraber KH. Human apolipoprotein E3 in aqueous solution. I. Evidence for two structural domains. J Biol Chem. 1988;263: 6240-8.
38. Gorshkova IN, Liu T, Kan HY, Chroni A, Zannis VI, Atkinson D. Structure and stability of apolipoprotein a-I in solution and in discoidal high-density lipoprotein probed by double charge ablation and deletion mutation. Biochemistry. 2006;45:1242-54. (Pubitemid 43167191)
39. Nolte RT, Atkinson D. Conformational analysis of apolipo-protein A-I and E-3 based on primary sequence and circular dichroism. Biophys J. 1992;63:1221-39. (Pubitemid 23004470)
40. Wilson C, Wardell MR, Weisgraber KH, Mahley RW, Agard DA. Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science. 1991;252:1817-22. (Pubitemid 21917100)
41. Steinmetz A, Kaffarnik H, Utermann G. Activation of phos-phatidylcholine- sterol acyltransferase by human apolipopro-tein E isoforms. Eur J Biochem. 1985;152:747-51. (Pubitemid 16192382)
42. Chen CH, Albers JJ. Activation of lecithin: cholesterol acyl-transferase by apolipoproteins E-2, E-3, and A-IV isolated from human plasma. Biochim Biophys Acta. 1985;836: 279-85. (Pubitemid 15244141)
43. Kypreos KE, Zannis VI. LDL receptor defi ciency or apoE mutations prevent remnant clearance and induce hypertrig-lyceridemia in mice. J Lipid Res. 2006;47:521-9. (Pubitemid 43345593)
44. Kypreos KE, Van Dijk KW, Havekes LM, Zannis VI. Generation of a recombinant apolipoprotein E variant with improved biological functions: hydrophobic residues (LEU-261, TRP-264, PHE-265, LEU-268, VAL-269) of apoE can account for the apoE-induced hypertriglyceridemia. J Biol Chem. 2005;280:6276-84. (Pubitemid 40341173)
45. Koukos G, Chroni A, Duka A, Kardassis D, Zannis VI. LCAT can rescue the abnormal phenotype produced by the natural ApoA-I mutations (Leu141Arg)Pisa and (Leu159Arg) FIN. Biochemistry. 2007;46:10713-21. (Pubitemid 47417263)